Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region.
Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD, Grimm RH Jr, Hansson L, Lacourcière Y, Muller JE, Sleight P, Weber MA, White WB, Williams GH, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group. Black HR, et al. Among authors: muller je. J Hypertens. 2005 May;23(5):1099-106. doi: 10.1097/01.hjh.0000166853.26087.22. J Hypertens. 2005. PMID: 15834298 Clinical Trial.
Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial.
Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, Hansson L, Lacoucière Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD, Anders RJ. Black HR, et al. Hypertension. 2001 Jan;37(1):12-18. doi: 10.1161/01.hyp.37.1.12. Hypertension. 2001. PMID: 11208750
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group. Black HR, et al. JAMA. 2003 Apr 23-30;289(16):2073-82. doi: 10.1001/jama.289.16.2073. JAMA. 2003. PMID: 12709465 Clinical Trial.
First-in-Human Experience With a Novel Multimodality DeepOCT-NIRS Intracoronary Imaging System.
Ali ZA, Dager A, Zúñiga M, Fonseca J, Arana C, Chamié D, Hill JM, Madder RD, Muller JE, Simonton CA, Tearney GJ, Stone GW. Ali ZA, et al. Among authors: muller je. J Soc Cardiovasc Angiogr Interv. 2024 Mar 5;3(4):101344. doi: 10.1016/j.jscai.2024.101344. eCollection 2024 Apr. J Soc Cardiovasc Angiogr Interv. 2024. PMID: 39130176 Free PMC article. No abstract available.
Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study.
Erlinge D, Maehara A, Ben-Yehuda O, Bøtker HE, Maeng M, Kjøller-Hansen L, Engstrøm T, Matsumura M, Crowley A, Dressler O, Mintz GS, Fröbert O, Persson J, Wiseth R, Larsen AI, Okkels Jensen L, Nordrehaug JE, Bleie Ø, Omerovic E, Held C, James SK, Ali ZA, Muller JE, Stone GW; PROSPECT II Investigators. Erlinge D, et al. Among authors: muller je. Lancet. 2021 Mar 13;397(10278):985-995. doi: 10.1016/S0140-6736(21)00249-X. Lancet. 2021. PMID: 33714389
328 results